胆管癌(CCA)是一种起源于胆管及其分支上皮的恶性肿瘤。由于其异质性高,早期没有特异性的临床指征,诊断常为晚期CCA。手术切除术后5年生存率(长期生存率)很差。吉西他滨联合铂类治疗方案已被用作晚期患者的一线化疗。近年来,针对多种恶...胆管癌(CCA)是一种起源于胆管及其分支上皮的恶性肿瘤。由于其异质性高,早期没有特异性的临床指征,诊断常为晚期CCA。手术切除术后5年生存率(长期生存率)很差。吉西他滨联合铂类治疗方案已被用作晚期患者的一线化疗。近年来,针对多种恶性肿瘤的靶向治疗取得了长足进展,在晚期CCA中显示出良好的疗效和安全性。然而,目前CCA的靶向治疗仍存在不良反应、耐药性、个体差异等诸多挑战。因此,研究需要进一步深入探索CCA恶性肿瘤的靶向治疗机制,开发更有效、更安全的药物,并根据患者特点精准制定方案,以进一步改善患者未来的预后。本文综述了CCA靶向治疗的最新进展,旨在为CCA靶向治疗的研究和临床工作提供策略。Cholangiocarcinoma (CCA) is a malignant tumor that originates from the epithelial epithelium of the bile ducts and their branches. Due to its high heterogeneity, there is no specific clinical indication for the early stage, and the diagnosis is often advanced CCA. The 5-year survival rate (long-term survival) after surgical resection is poor. Gemcitabine plus platinum-based regimens have been used as first-line chemotherapy for patients with advanced disease. In recent years, significant progress has been made in targeted therapy for a variety of malignancies, showing good efficacy and safety in advanced CCA. However, there are still many challenges in the targeted therapy of CCA, such as adverse reactions, drug resistance, and individual differences. Therefore, it is necessary to further explore the targeted therapy mechanism of CCA malignancies, develop more effective and safer drugs, and formulate precise plans according to the characteristics of patients to further improve the prognosis of patients in the future. This article reviews the latest advances in CCA-targeted therapy, aiming to provide strategies for the research and clinical work of CCA-targeted therapy.展开更多
随着科学技术的进步,胰腺癌作为一种高度致命性肿瘤,其治疗策略不断革新。本综述分析了胰腺癌的手术治疗、影像学诊断、免疫治疗以及相关生物标志物的研究进展,并讨论了肿瘤治疗副作用和对策,以及其他癌症的相关研究。特别关注了胰腺癌...随着科学技术的进步,胰腺癌作为一种高度致命性肿瘤,其治疗策略不断革新。本综述分析了胰腺癌的手术治疗、影像学诊断、免疫治疗以及相关生物标志物的研究进展,并讨论了肿瘤治疗副作用和对策,以及其他癌症的相关研究。特别关注了胰腺癌在免疫治疗方面的最新动态,包括胰腺癌腹水模型的建立,抗IL-9抗体治疗的前景,以及直接靶向PD-1的治疗方法。同时,也着眼于通过整合生物信息学分析来揭示胰腺癌分子过程的异常和信号通路的失调。此外,综述凸显了研究方法和医学文献翻译在当前课题中的重要性。通过阐述各研究领域内的先进成果和现存的挑战,为胰腺癌免疫治疗的临床应用前景提供了一定的参考。With the advancement of science and technology, pancreatic cancer, a highly lethal tumor, has experienced revolutionary treatment strategies. This review analyzes the progress in surgical treatment, radiological diagnosis, immunotherapy, and related biomarkers for pancreatic cancer, and discusses the side effects of tumor treatment and strategies to mitigate them, along with relevant research on other cancers. The review particularly focuses on the latest developments in immunotherapy for pancreatic cancer, including the establishment of a pancreatic cancer ascites mouse model, the prospective role of anti-IL-9 antibody therapy, and direct targeting of the PD-1 immune checkpoint. Additionally, it highlights the relevance of integrative bioinformatics analyses for uncovering aberrations in molecular processes and signaling pathway dysregulation in pancreatic cancer. Moreover, the review underscores the significance of research methodologies and the translation of medical literature in this field. By articulating the pioneering findings and ongoing challenges within each domain, the review provides insights into the potential clinical application prospects for immunotherapy in pancreatic cancer.展开更多
文摘胆管癌(CCA)是一种起源于胆管及其分支上皮的恶性肿瘤。由于其异质性高,早期没有特异性的临床指征,诊断常为晚期CCA。手术切除术后5年生存率(长期生存率)很差。吉西他滨联合铂类治疗方案已被用作晚期患者的一线化疗。近年来,针对多种恶性肿瘤的靶向治疗取得了长足进展,在晚期CCA中显示出良好的疗效和安全性。然而,目前CCA的靶向治疗仍存在不良反应、耐药性、个体差异等诸多挑战。因此,研究需要进一步深入探索CCA恶性肿瘤的靶向治疗机制,开发更有效、更安全的药物,并根据患者特点精准制定方案,以进一步改善患者未来的预后。本文综述了CCA靶向治疗的最新进展,旨在为CCA靶向治疗的研究和临床工作提供策略。Cholangiocarcinoma (CCA) is a malignant tumor that originates from the epithelial epithelium of the bile ducts and their branches. Due to its high heterogeneity, there is no specific clinical indication for the early stage, and the diagnosis is often advanced CCA. The 5-year survival rate (long-term survival) after surgical resection is poor. Gemcitabine plus platinum-based regimens have been used as first-line chemotherapy for patients with advanced disease. In recent years, significant progress has been made in targeted therapy for a variety of malignancies, showing good efficacy and safety in advanced CCA. However, there are still many challenges in the targeted therapy of CCA, such as adverse reactions, drug resistance, and individual differences. Therefore, it is necessary to further explore the targeted therapy mechanism of CCA malignancies, develop more effective and safer drugs, and formulate precise plans according to the characteristics of patients to further improve the prognosis of patients in the future. This article reviews the latest advances in CCA-targeted therapy, aiming to provide strategies for the research and clinical work of CCA-targeted therapy.
文摘随着科学技术的进步,胰腺癌作为一种高度致命性肿瘤,其治疗策略不断革新。本综述分析了胰腺癌的手术治疗、影像学诊断、免疫治疗以及相关生物标志物的研究进展,并讨论了肿瘤治疗副作用和对策,以及其他癌症的相关研究。特别关注了胰腺癌在免疫治疗方面的最新动态,包括胰腺癌腹水模型的建立,抗IL-9抗体治疗的前景,以及直接靶向PD-1的治疗方法。同时,也着眼于通过整合生物信息学分析来揭示胰腺癌分子过程的异常和信号通路的失调。此外,综述凸显了研究方法和医学文献翻译在当前课题中的重要性。通过阐述各研究领域内的先进成果和现存的挑战,为胰腺癌免疫治疗的临床应用前景提供了一定的参考。With the advancement of science and technology, pancreatic cancer, a highly lethal tumor, has experienced revolutionary treatment strategies. This review analyzes the progress in surgical treatment, radiological diagnosis, immunotherapy, and related biomarkers for pancreatic cancer, and discusses the side effects of tumor treatment and strategies to mitigate them, along with relevant research on other cancers. The review particularly focuses on the latest developments in immunotherapy for pancreatic cancer, including the establishment of a pancreatic cancer ascites mouse model, the prospective role of anti-IL-9 antibody therapy, and direct targeting of the PD-1 immune checkpoint. Additionally, it highlights the relevance of integrative bioinformatics analyses for uncovering aberrations in molecular processes and signaling pathway dysregulation in pancreatic cancer. Moreover, the review underscores the significance of research methodologies and the translation of medical literature in this field. By articulating the pioneering findings and ongoing challenges within each domain, the review provides insights into the potential clinical application prospects for immunotherapy in pancreatic cancer.
